Publication AWA
At the Public Information Bulletin of the Agency for Health Technology Assessment and Tarification (AWA) has published review analyses for the evaluation of reimbursement applications:
- Tagrisso (osimertinib) in the treatment of lung cancer and pleural mesothelioma
- Fabhalta (iptacopan) in the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH)
We encourage you to read the full documents and submit comments within the prescribed period of 7 days from the date of publication.
